 | • レポートコード：MRC2-11QY07682 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は転移性ブドウ膜黒色腫治療薬のグローバル市場について調査・分析したレポートです。種類別（スニチニブリンゴ酸塩、ビンクリスチン硫酸塩リポソーム、LY-2801653、酢酸ソトラスタウリン、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別転移性ブドウ膜黒色腫治療薬の競争状況、市場シェア ・世界の転移性ブドウ膜黒色腫治療薬市場：種類別市場規模 2015年-2020年（スニチニブリンゴ酸塩、ビンクリスチン硫酸塩リポソーム、LY-2801653、酢酸ソトラスタウリン、その他） ・世界の転移性ブドウ膜黒色腫治療薬市場：種類別市場規模予測 2021年-2026年（スニチニブリンゴ酸塩、ビンクリスチン硫酸塩リポソーム、LY-2801653、酢酸ソトラスタウリン、その他） ・世界の転移性ブドウ膜黒色腫治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の転移性ブドウ膜黒色腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の転移性ブドウ膜黒色腫治療薬市場分析：米国、カナダ ・ヨーロッパの転移性ブドウ膜黒色腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの転移性ブドウ膜黒色腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の転移性ブドウ膜黒色腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの転移性ブドウ膜黒色腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca PLC、Eli Lilly and Company、Novartis AG、Pfizer Inc.、Spectrum Pharmaceuticals, Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Metastatic Uveal Melanoma Thereapeutics Market
The global Metastatic Uveal Melanoma Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Metastatic Uveal Melanoma Thereapeutics Scope and Market Size
Metastatic Uveal Melanoma Thereapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Uveal Melanoma Thereapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Metastatic Uveal Melanoma Thereapeutics market is segmented into
Sunitinib Malate
Vincristine Sulfate Liposomal
LY-2801653
Sotrastaurin Acetate
Others
Segment by Application, the Metastatic Uveal Melanoma Thereapeutics market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Metastatic Uveal Melanoma Thereapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Metastatic Uveal Melanoma Thereapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Metastatic Uveal Melanoma Thereapeutics Market Share Analysis
Metastatic Uveal Melanoma Thereapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Metastatic Uveal Melanoma Thereapeutics business, the date to enter into the Metastatic Uveal Melanoma Thereapeutics market, Metastatic Uveal Melanoma Thereapeutics product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca PLC
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Spectrum Pharmaceuticals, Inc.
…
1 Study Coverage
1.1 Metastatic Uveal Melanoma Thereapeutics Product Introduction
1.2 Market Segments
1.3 Key Metastatic Uveal Melanoma Thereapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Type
1.4.2 Sunitinib Malate
1.4.3 Vincristine Sulfate Liposomal
1.4.4 LY-2801653
1.4.5 Sotrastaurin Acetate
1.4.6 Others
1.5 Market by Application
1.5.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size, Estimates and Forecasts
2.1.1 Global Metastatic Uveal Melanoma Thereapeutics Revenue 2015-2026
2.1.2 Global Metastatic Uveal Melanoma Thereapeutics Sales 2015-2026
2.2 Global Metastatic Uveal Melanoma Thereapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Metastatic Uveal Melanoma Thereapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Metastatic Uveal Melanoma Thereapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Metastatic Uveal Melanoma Thereapeutics Competitor Landscape by Players
3.1 Metastatic Uveal Melanoma Thereapeutics Sales by Manufacturers
3.1.1 Metastatic Uveal Melanoma Thereapeutics Sales by Manufacturers (2015-2020)
3.1.2 Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Metastatic Uveal Melanoma Thereapeutics Revenue by Manufacturers
3.2.1 Metastatic Uveal Melanoma Thereapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Metastatic Uveal Melanoma Thereapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Metastatic Uveal Melanoma Thereapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Metastatic Uveal Melanoma Thereapeutics Revenue in 2019
3.2.5 Global Metastatic Uveal Melanoma Thereapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Metastatic Uveal Melanoma Thereapeutics Price by Manufacturers
3.4 Metastatic Uveal Melanoma Thereapeutics Manufacturing Base Distribution, Product Types
3.4.1 Metastatic Uveal Melanoma Thereapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Metastatic Uveal Melanoma Thereapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Metastatic Uveal Melanoma Thereapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2015-2020)
4.1.1 Global Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020)
4.1.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue by Type (2015-2020)
4.1.3 Metastatic Uveal Melanoma Thereapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Metastatic Uveal Melanoma Thereapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Metastatic Uveal Melanoma Thereapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2015-2020)
5.1.1 Global Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020)
5.1.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue by Application (2015-2020)
5.1.3 Metastatic Uveal Melanoma Thereapeutics Price by Application (2015-2020)
5.2 Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Metastatic Uveal Melanoma Thereapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Metastatic Uveal Melanoma Thereapeutics by Country
6.1.1 North America Metastatic Uveal Melanoma Thereapeutics Sales by Country
6.1.2 North America Metastatic Uveal Melanoma Thereapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Type
6.3 North America Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Metastatic Uveal Melanoma Thereapeutics by Country
7.1.1 Europe Metastatic Uveal Melanoma Thereapeutics Sales by Country
7.1.2 Europe Metastatic Uveal Melanoma Thereapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Type
7.3 Europe Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Metastatic Uveal Melanoma Thereapeutics by Region
8.1.1 Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales by Region
8.1.2 Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Type
8.3 Asia Pacific Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Metastatic Uveal Melanoma Thereapeutics by Country
9.1.1 Latin America Metastatic Uveal Melanoma Thereapeutics Sales by Country
9.1.2 Latin America Metastatic Uveal Melanoma Thereapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Type
9.3 Central & South America Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics by Country
10.1.1 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales by Country
10.1.2 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca PLC
11.1.1 AstraZeneca PLC Corporation Information
11.1.2 AstraZeneca PLC Description and Business Overview
11.1.3 AstraZeneca PLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca PLC Metastatic Uveal Melanoma Thereapeutics Products Offered
11.1.5 AstraZeneca PLC Related Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Corporation Information
11.2.2 Eli Lilly and Company Description and Business Overview
11.2.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eli Lilly and Company Metastatic Uveal Melanoma Thereapeutics Products Offered
11.2.5 Eli Lilly and Company Related Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Description and Business Overview
11.3.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis AG Metastatic Uveal Melanoma Thereapeutics Products Offered
11.3.5 Novartis AG Related Developments
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Corporation Information
11.4.2 Pfizer Inc. Description and Business Overview
11.4.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer Inc. Metastatic Uveal Melanoma Thereapeutics Products Offered
11.4.5 Pfizer Inc. Related Developments
11.5 Spectrum Pharmaceuticals, Inc.
11.5.1 Spectrum Pharmaceuticals, Inc. Corporation Information
11.5.2 Spectrum Pharmaceuticals, Inc. Description and Business Overview
11.5.3 Spectrum Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Spectrum Pharmaceuticals, Inc. Metastatic Uveal Melanoma Thereapeutics Products Offered
11.5.5 Spectrum Pharmaceuticals, Inc. Related Developments
11.1 AstraZeneca PLC
11.1.1 AstraZeneca PLC Corporation Information
11.1.2 AstraZeneca PLC Description and Business Overview
11.1.3 AstraZeneca PLC Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca PLC Metastatic Uveal Melanoma Thereapeutics Products Offered
11.1.5 AstraZeneca PLC Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Metastatic Uveal Melanoma Thereapeutics Market Estimates and Projections by Region
12.1.1 Global Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Metastatic Uveal Melanoma Thereapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Metastatic Uveal Melanoma Thereapeutics Sales Forecast (2021-2026)
12.2.2 North America: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Metastatic Uveal Melanoma Thereapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Metastatic Uveal Melanoma Thereapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Metastatic Uveal Melanoma Thereapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Metastatic Uveal Melanoma Thereapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Metastatic Uveal Melanoma Thereapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Metastatic Uveal Melanoma Thereapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Metastatic Uveal Melanoma Thereapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Metastatic Uveal Melanoma Thereapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Metastatic Uveal Melanoma Thereapeutics Market Segments
Table 2. Ranking of Global Top Metastatic Uveal Melanoma Thereapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Sunitinib Malate
Table 5. Major Manufacturers of Vincristine Sulfate Liposomal
Table 6. Major Manufacturers of LY-2801653
Table 7. Major Manufacturers of Sotrastaurin Acetate
Table 8. Major Manufacturers of Others
Table 9. Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Metastatic Uveal Melanoma Thereapeutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Metastatic Uveal Melanoma Thereapeutics Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Regions (2015-2020)
Table 13. Global Metastatic Uveal Melanoma Thereapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Metastatic Uveal Melanoma Thereapeutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Metastatic Uveal Melanoma Thereapeutics Sales Share by Manufacturers (2015-2020)
Table 16. Global Metastatic Uveal Melanoma Thereapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Metastatic Uveal Melanoma Thereapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Uveal Melanoma Thereapeutics as of 2019)
Table 18. Metastatic Uveal Melanoma Thereapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Metastatic Uveal Melanoma Thereapeutics Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Metastatic Uveal Melanoma Thereapeutics Price (2015-2020) (USD/Pcs)
Table 21. Metastatic Uveal Melanoma Thereapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Metastatic Uveal Melanoma Thereapeutics Product Type
Table 23. Date of International Manufacturers Enter into Metastatic Uveal Melanoma Thereapeutics Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 26. Global Metastatic Uveal Melanoma Thereapeutics Sales Share by Type (2015-2020)
Table 27. Global Metastatic Uveal Melanoma Thereapeutics Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Metastatic Uveal Melanoma Thereapeutics Revenue Share by Type (2015-2020)
Table 29. Metastatic Uveal Melanoma Thereapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 31. Global Metastatic Uveal Melanoma Thereapeutics Sales Share by Application (2015-2020)
Table 32. North America Metastatic Uveal Melanoma Thereapeutics Sales by Country (2015-2020) (K Pcs)
Table 33. North America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country (2015-2020)
Table 34. North America Metastatic Uveal Melanoma Thereapeutics Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country (2015-2020)
Table 36. North America Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 37. North America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Table 38. North America Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 39. North America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Table 40. Europe Metastatic Uveal Melanoma Thereapeutics Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country (2015-2020)
Table 42. Europe Metastatic Uveal Melanoma Thereapeutics Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country (2015-2020)
Table 44. Europe Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Table 46. Europe Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Table 56. Latin America Metastatic Uveal Melanoma Thereapeutics Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Metastatic Uveal Melanoma Thereapeutics Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country (2015-2020)
Table 60. Latin America Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Table 62. Latin America Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Table 72. AstraZeneca PLC Corporation Information
Table 73. AstraZeneca PLC Description and Major Businesses
Table 74. AstraZeneca PLC Metastatic Uveal Melanoma Thereapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. AstraZeneca PLC Product
Table 76. AstraZeneca PLC Recent Development
Table 77. Eli Lilly and Company Corporation Information
Table 78. Eli Lilly and Company Description and Major Businesses
Table 79. Eli Lilly and Company Metastatic Uveal Melanoma Thereapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Eli Lilly and Company Product
Table 81. Eli Lilly and Company Recent Development
Table 82. Novartis AG Corporation Information
Table 83. Novartis AG Description and Major Businesses
Table 84. Novartis AG Metastatic Uveal Melanoma Thereapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Novartis AG Product
Table 86. Novartis AG Recent Development
Table 87. Pfizer Inc. Corporation Information
Table 88. Pfizer Inc. Description and Major Businesses
Table 89. Pfizer Inc. Metastatic Uveal Melanoma Thereapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Pfizer Inc. Product
Table 91. Pfizer Inc. Recent Development
Table 92. Spectrum Pharmaceuticals, Inc. Corporation Information
Table 93. Spectrum Pharmaceuticals, Inc. Description and Major Businesses
Table 94. Spectrum Pharmaceuticals, Inc. Metastatic Uveal Melanoma Thereapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Spectrum Pharmaceuticals, Inc. Product
Table 96. Spectrum Pharmaceuticals, Inc. Recent Development
Table 97. Global Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 98. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 99. Global Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 100. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 101. North America: Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 102. North America: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Europe: Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. Europe: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Asia Pacific: Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 106. Asia Pacific: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 107. Latin America: Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. Latin America: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Middle East and Africa: Metastatic Uveal Melanoma Thereapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Middle East and Africa: Metastatic Uveal Melanoma Thereapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 112. Key Challenges
Table 113. Market Risks
Table 114. Main Points Interviewed from Key Metastatic Uveal Melanoma Thereapeutics Players
Table 115. Metastatic Uveal Melanoma Thereapeutics Customers List
Table 116. Metastatic Uveal Melanoma Thereapeutics Distributors List
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Uveal Melanoma Thereapeutics Product Picture
Figure 2. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Sunitinib Malate Product Picture
Figure 4. Vincristine Sulfate Liposomal Product Picture
Figure 5. LY-2801653 Product Picture
Figure 6. Sotrastaurin Acetate Product Picture
Figure 7. Others Product Picture
Figure 8. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Metastatic Uveal Melanoma Thereapeutics Report Years Considered
Figure 13. Global Metastatic Uveal Melanoma Thereapeutics Market Size 2015-2026 (US$ Million)
Figure 14. Global Metastatic Uveal Melanoma Thereapeutics Sales 2015-2026 (K Pcs)
Figure 15. Global Metastatic Uveal Melanoma Thereapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Region (2015-2020)
Figure 17. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Region in 2019
Figure 18. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Region (2015-2020)
Figure 19. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Region in 2019
Figure 20. Global Metastatic Uveal Melanoma Thereapeutics Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Metastatic Uveal Melanoma Thereapeutics Revenue in 2019
Figure 22. Metastatic Uveal Melanoma Thereapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type (2015-2020)
Figure 24. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Type in 2019
Figure 25. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type (2015-2020)
Figure 26. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type in 2019
Figure 27. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Price Range (2015-2020)
Figure 28. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application (2015-2020)
Figure 29. Global Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Application in 2019
Figure 30. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Application (2015-2020)
Figure 31. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Application in 2019
Figure 32. North America Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country in 2019
Figure 35. North America Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country in 2019
Figure 36. U.S. Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Metastatic Uveal Melanoma Thereapeutics Market Share by Type in 2019
Figure 41. North America Metastatic Uveal Melanoma Thereapeutics Market Share by Application in 2019
Figure 42. Europe Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country in 2019
Figure 45. Europe Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country in 2019
Figure 46. Germany Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Metastatic Uveal Melanoma Thereapeutics Market Share by Type in 2019
Figure 57. Europe Metastatic Uveal Melanoma Thereapeutics Market Share by Application in 2019
Figure 58. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Region in 2019
Figure 61. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Region in 2019
Figure 62. China Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Market Share by Type in 2019
Figure 85. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Market Share by Application in 2019
Figure 86. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country in 2019
Figure 89. Latin America Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country in 2019
Figure 90. Mexico Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Metastatic Uveal Melanoma Thereapeutics Market Share by Type in 2019
Figure 97. Latin America Metastatic Uveal Melanoma Thereapeutics Market Share by Application in 2019
Figure 98. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Country in 2019
Figure 102. Turkey Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Market Share by Type in 2019
Figure 109. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Market Share by Application in 2019
Figure 110. North America Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Metastatic Uveal Melanoma Thereapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
ドラベ症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Dravet Syndrome Thereapeutics Scope and Market Size Dra…- 黒色腫の世界市場（～2026年） Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are mo…
- 黒色腫がんの世界市場（～2026年） Melanoma Cancer is a skin cancer that develops due to expose of UV rays on the skin. Increasing incidence of melanoma across the globe and rising ozone layer depletion due to global warming are the major factors that are driving the market during the forecast period. Additionally, overexposure to ra…
- 転移性膵臓がん治療の世界市場（～2026年） Metastatic pancreatic cancer treatment, when cancer spreads outside of the pancreas, surgery may or may not be recommended. It’s more common for oncologists to recommend systemic treatments (which can circulate throughout the entire body and destroy cancerous cells in multiple locations) for metasta…
- 転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…